

**Prevalence of spondyloarthritis among patients
Presented with inflammatory low back pain**

Thesis

Submitted for partial fulfillment of Master
Degree in Internal Medicine

Presented by

Wael Ahmed Gad El karim
(M.B.B.C h)

Under supervision of

Prof. Dr.Mohammed Salah El Din Abd El Baky

Professor of Internal Medicine and Rheumatology

Head of Rheumatology Unite

Faculty of Medicine

Ain Shams University

Dr.Amina Badr El Din Abd El Aziz

Assit . professor of Internal Medicine

Faculty of Medicine

Ain Shams University

Dr.Sherine M. Hussni Hamza

Lecturer of Internal Medicine

Faculty of Medicine

Ain Shams University

2009

دراسة عن معدل انتشار مرض التهاب العمود الفقري التيبسي
بين مرضى ألم أسفل الظهر

مقدمة من
الطبيب / وائل أحمد جاد الكريم
بكالوريوس الطب و الجراحة
2002

تحت اشراف
أ.د / محمد صلاح الدين عبد الباقي
أستاذ أمراض الباطنة العامة و رئيس وحدة الروماتيزم
كلية الطب (جامعة عين شمس)

د / أمينة بدر الدين عبد العزيز
أستاذ مساعد أمراض الباطنة
كلية الطب (جامعة عين شمس)

د /شيرين حسني حمزة
مدرس الباطنة العامة
كلية الطب (جامعة عين شمس)

2009



قالوا
عجباً إنك لا علم لنا إلا ما علمتنا
إنك أنت العظيم الحكيم
صدق الله العظيم

سوره البقرة آیه رقم 32

List of Abbreviations	
ACR	American college of rheumatology.
ANA	Antinuclear antibodies.
Anti-CCP	Anti-cyclic citrullinated peptide.
ARF	Acute rheumatic fever.
AS	Ankylosing spondylitis.
ASAS	The Assessment of Spondylo-Arthritis international Society.
BASDAI	The Bath Ankylosing Spondylitis Disease Activity index.
BASFI	The Bath Ankylosing Spondylitis Functional index.
BCG	Bacillus Calmette-Guerin.
BMP	Bone morphogenetic proteins.
CDC	The Centers for Disease Control and Prevention.
COX-2 inhibitors	Cyclooxygenase-2 inhibitors.
CRP	C-reactive protein.
CSI	Cyclosporine A.
CTL	Cytotoxic T lymphocytes.
DAS	The Disease Activity Score.
DGI	Disseminated gonococcal infection.
DIP joint	Distal interphalangeal joint.
ER	Endoplasmic reticulum.
ESR	Erythrocyte sedimentation rate.
ESSEG	European Spondyloarthropathy Study group.
EULAR	European League Against Rheumatism.
FDA	Food and Drug Administration.
FSE	Fast spin echo.
GFR	Glomerular filtration rate.
HAQ	Health assessment questionnaire.
HF	Heart failure.
IBD	Inflammatory bowel disease.
IFN-alpha	Interferon-alpha.
IMPACT	The Infliximab Multinational Psoriatic Arthritis

	Controlled Trials.
KIRs	The killer Ig-like receptors.
MCP Joint	Metacarpophalangeal Joint.
MHC	Major histocompatibility locus.
MTP Joint	Metatarsophalangeal Joint.
MTX	Methotrexate.
NKRs	Natural killer receptors.
NSAIDs	Nonsteroidal anti-inflammatory drugs.
PASI	Psoriasis activity severity index.
PCR	Polymerase chain reaction.
PIP	Proximal interphalangeal.
PML	Progressive multifocal leukoencephalopathy.
PPL	Purified protein derivative.
PsA	Psoriatic arthritis.
PsARC	Psoriatic arthritis Response Criteria.
PSRA	Poststreptococcal reactive arthritis.
SEC	Synovio-entheseal complex.
SPA	Spondyloarthritis.
STIR	Short tau inversion recovery.
TAP	Transporter associated with antigen processing.
TCR	The T cell receptors.
TNF	Tumor necrosis factor.
USPA	Undifferentiated spondyloarthritis.
VIPR1	Human vasoactive intestinal peptide receptor.

CONTENTS

Chapter	Page
• Acknowledgement	i
• List of Figures.	ii
• List of Tables.	iii
• List of Abbreviations.	iv
Introduction	1
Aim of the work.....	3
Review of Literature.....	
❖ Chapter I: Classifications and Pathogenesis of Spondyloarthropathy.	4
❖ Chapter II: Ankylosing spondylitis.	31
❖ Chapter III: Psoriatic Arthritis.	89
❖ Chapter IV: Reactive Arthritis.	131
❖ Chapter V: Spondyloarthoropathy associated with Inflammatory Bowel Disease.	161
❖ Patients and methods	181
❖ Results	183
❖ Discussion	198
References.....	206
Arabic Summary.....	1

ACKNOWLEDGEMENT

First of all, I would like to thank **ALLAH** who helped me to complete this work.

Then I wish to express my sincere thanks and deep gratitude to **Prof. Dr. Mohamed Salah Eldin Abd ElBaky**, Professor of Internal Medicine and Rheumatology, Head of Rheumatology unit. Ain Shams University for giving me the honor of working under his supervision, suggesting the topics of this thesis. I gratefully acknowledge his willingness to give all efforts and time unsparingly to bring this work forwards.

Also, I would like to thank **Prof. Dr. Amina Badr EL deen assistant** Professor of Internal Medicine and Rheumatology, Ain Shams University for his supervision and kind cooperation.

I am profoundly grateful to **Dr. Shreen Mohammed Hossni** Lecturer of Internal Medicine and Rheumatology, Ain Shams University for his valuable assistance, continuous guidance and encouragement during this study.

Finally, I thank my family for helping me to end this work.

Wael Ahmed

LIST OF FIGURES

Figure	Title	Page
Fig. 1	HLA class I molecule.	13
Fig. 2	HLA-B27 peptide presentation.	16
Fig. 3	Model of the HLA-B27 heavy-chain homodimer.	20
Fig. 4	Potential consequences of HLA-B27 misfolding.	23
Fig. 5	Illustration of a typical enthesis.	29
Fig. 6	Progression of postural changes with ankylosing spondylitis.	33
Fig. 7	Masking of flexion deformity of the hip in AS.	38
Fig. 8	Unmasking of flexion hip deformity in AS.	39
Fig. 9	Testing for low back flexion.	41
Fig. 10	Cervical flexion deformity in AS.	42
Fig. 11	Testing for sacroiliac tenderness.	43
Fig. 12	Testing for sacroiliac pain	44
Fig. 13	Testing for sacroiliac pain.	44
Fig. 14	Early sacroiliitis in AS	52
Fig. 15	Fusion of sacroiliac joints in AS.	52
Fig. 16	Bamboo spine in AS.	53
Fig. 17	Ankylosing spondylitis.	54

Fig. 18	(DIP) joint involvement.	97
Fig. 19	Arthritis mutilans.	98
Fig. 20	Onycholysis and Dactylitis.	100
Fig. 21	Sequential nail changes in psoriasis.	100
Fig. 22	DIP involvement in psoriatic arthritis.	103
Fig. 23	Arthritis mutilans in psoriatic arthritis.	104
Fig. 24	Circinate balanitis.	136
Fig. 25	Keratoderma blennorrhagica.	137
Fig. 26	Conjunctivitis and anterior uveitis in reactive arthritis.	137
Fig. 27	Sausage digit (left 2nd toe).	138
Fig. 28	Asymmetrical arthritis of the knees.	138
Fig. 29	Sacroilitis.	167

LIST OF TABELS

Table	Title	Page
Table 1	Infliximab adverse events.	76
Table 2	Etanercept adverse events.	79
Table 3	Etanercept vs. Infliximab: (Pharmacologic Characteristics).	80
Table 4	Treatment options for trichomoniasis.	158
Table 5	Treatment options for chlamydia trachomatis infection and related clinical syndromes.	106

List of Abbreviations	
ACR	American college of rheumatology.
ANA	Antinuclear antibodies.
Anti-CCP	Anti-cyclic citrullinated peptide.
ARF	Acute rheumatic fever.
AS	Ankylosing spondylitis.
ASAS	The Assessment of Spondylo-Arthritis international Society.
BASDAI	The Bath Ankylosing Spondylitis Disease Activity index.
BASFI	The Bath Ankylosing Spondylitis Functional index.
BCG	Bacillus Calmette-Guerin.
BMP	Bone morphogenetic proteins.
CDC	The Centers for Disease Control and Prevention.
COX-2 inhibitors	Cyclooxygenase-2 inhibitors.
CRP	C-reactive protein.
CSI	Cyclosporine A.
CTL	Cytotoxic T lymphocytes.
DAS	The Disease Activity Score.
DGI	Disseminated gonococcal infection.
DIP joint	Distal interphalangeal joint.
ER	Endoplasmic reticulum.
ESR	Erythrocyte sedimentation rate.
ESSEG	European Spondyloarthropathy Study group.
EULAR	European League Against Rheumatism.
FDA	Food and Drug Administration.
FSE	Fast spin echo.
GFR	Glomerular filtration rate.
HAQ	Health assessment questionnaire.
HF	Heart failure.
IBD	Inflammatory bowel disease.
IFN-alpha	Interferon-alpha.
IMPACT	The International Multidisciplinary Decision Analysis

